MX2020002198A - Anticuerpos anti-cd166 activables y métodos de uso de los mismos. - Google Patents
Anticuerpos anti-cd166 activables y métodos de uso de los mismos.Info
- Publication number
- MX2020002198A MX2020002198A MX2020002198A MX2020002198A MX2020002198A MX 2020002198 A MX2020002198 A MX 2020002198A MX 2020002198 A MX2020002198 A MX 2020002198A MX 2020002198 A MX2020002198 A MX 2020002198A MX 2020002198 A MX2020002198 A MX 2020002198A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antibodies
- activatable anti
- activatable antibodies
- specifically bind
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Abstract
En el presente documento se proporcionan anticuerpos activables que se unen específicamente a CD166 y anticuerpos activables conjugados que se unen específicamente a CD166. También se proporcionan métodos para fabricar y usar estos anticuerpos activables en una variedad de indicaciones terapéuticas, diagnósticas y profilácticas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762552345P | 2017-08-30 | 2017-08-30 | |
US201762553098P | 2017-08-31 | 2017-08-31 | |
US201762554919P | 2017-09-06 | 2017-09-06 | |
PCT/US2018/048965 WO2019046652A1 (en) | 2017-08-30 | 2018-08-30 | ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002198A true MX2020002198A (es) | 2020-07-20 |
Family
ID=63678683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002198A MX2020002198A (es) | 2017-08-30 | 2018-08-30 | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190117789A1 (es) |
EP (1) | EP3676293A1 (es) |
JP (1) | JP2020532509A (es) |
KR (1) | KR20200058406A (es) |
CN (1) | CN111212853A (es) |
AU (1) | AU2018324097A1 (es) |
BR (1) | BR112020004231A2 (es) |
CA (1) | CA3074112A1 (es) |
IL (1) | IL272703A (es) |
MX (1) | MX2020002198A (es) |
SG (1) | SG11202001173VA (es) |
WO (1) | WO2019046652A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2984948A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
EA202090247A1 (ru) | 2017-07-14 | 2020-05-12 | Цитомкс Терапьютикс, Инк. | Антитела против cd166 и их применения |
ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
JP2021524756A (ja) | 2018-05-14 | 2021-09-16 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なサイトカインポリペプチド及びその使用方法 |
WO2020092881A1 (en) * | 2018-11-02 | 2020-05-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
JP2022532217A (ja) | 2019-05-14 | 2022-07-13 | ウェアウルフ セラピューティクス, インコーポレイテッド | 分離部分及びその使用方法 |
WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
WO2023183923A1 (en) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1988001513A1 (en) | 1986-08-28 | 1988-03-10 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF |
US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
CN103688404B (zh) * | 2011-07-20 | 2016-06-08 | 株式会社村田制作所 | 全固体电池及其制造方法 |
WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
JP6494533B2 (ja) * | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
US9626054B2 (en) * | 2014-12-19 | 2017-04-18 | Salt International Corp. | Capacitive sensing device and method that reduces influence from transient environmental changes |
CA2984948A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
-
2018
- 2018-08-30 MX MX2020002198A patent/MX2020002198A/es unknown
- 2018-08-30 EP EP18773905.7A patent/EP3676293A1/en active Pending
- 2018-08-30 JP JP2020511473A patent/JP2020532509A/ja active Pending
- 2018-08-30 KR KR1020207008316A patent/KR20200058406A/ko not_active Application Discontinuation
- 2018-08-30 CN CN201880066681.8A patent/CN111212853A/zh active Pending
- 2018-08-30 BR BR112020004231-5A patent/BR112020004231A2/pt unknown
- 2018-08-30 CA CA3074112A patent/CA3074112A1/en active Pending
- 2018-08-30 SG SG11202001173VA patent/SG11202001173VA/en unknown
- 2018-08-30 AU AU2018324097A patent/AU2018324097A1/en not_active Abandoned
- 2018-08-30 US US16/118,295 patent/US20190117789A1/en not_active Abandoned
- 2018-08-30 WO PCT/US2018/048965 patent/WO2019046652A1/en unknown
-
2020
- 2020-02-16 IL IL272703A patent/IL272703A/en unknown
- 2020-07-21 US US16/934,955 patent/US20210100913A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL272703A (en) | 2020-04-30 |
CN111212853A (zh) | 2020-05-29 |
US20190117789A1 (en) | 2019-04-25 |
WO2019046652A1 (en) | 2019-03-07 |
SG11202001173VA (en) | 2020-03-30 |
EP3676293A1 (en) | 2020-07-08 |
US20210100913A1 (en) | 2021-04-08 |
KR20200058406A (ko) | 2020-05-27 |
BR112020004231A2 (pt) | 2020-09-08 |
AU2018324097A1 (en) | 2020-03-12 |
CA3074112A1 (en) | 2019-03-07 |
JP2020532509A (ja) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002198A (es) | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. | |
MX2021014735A (es) | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. | |
MX2021005116A (es) | Anticuerpos activables anti-cd166 y metodos de uso de estos. | |
AU2018278327A1 (en) | Activatable anti-pdl1 antibodies and methods of use thereof | |
ZA201707645B (en) | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof | |
MX2021006786A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
MX2017008819A (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
WO2016014974A3 (en) | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same | |
PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
MX2021013467A (es) | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
BR112017023868A2 (pt) | anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
BR112016001611A2 (pt) | Anticorpos multiespecíficos, anticorpos ativáveis multiespecíficos e métodos de utilização dos mesmos | |
WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
CR20200206A (es) | Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
WO2015153997A3 (en) | Notch3 antibodies and uses thereof | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |